{"hands_on_practices": [{"introduction": "Predicting a drug's metabolic fate begins with identifying its most vulnerable points of attack by Phase I enzymes. This exercise challenges you to apply fundamental principles of chemical reactivity, such as bond dissociation energies and electronic effects, to determine the most probable site of initial oxidation on a hypothetical drug molecule. Mastering this skill is crucial for medicinal chemists and pharmacologists in designing more stable drugs and anticipating metabolic pathways [@problem_id:4548577].", "problem": "A lipophilic, overall neutral small-molecule drug contains a single tertiary aliphatic amine (bearing at least one $\\alpha$-carbon with C–H bonds) and elsewhere on the scaffold a remote isopropyl group attached to a saturated, non-benzylic, non-allylic carbon. The drug is incubated with human liver microsomes. Using first principles for Phase I functionalization reactions, predict the most likely first transformation and justify your choice by comparing bond dissociation energies and electronic factors at the candidate sites. Select the single best answer.\n\nA. Cytochrome P450 (CYP)-mediated oxidative N-dealkylation initiated by hydrogen abstraction at the carbon $\\alpha$ to the tertiary amine, proceeding through a carbinolamine that fragments to a secondary amine and a carbonyl compound.\n\nB. Flavin-containing monooxygenase (FMO)-mediated N-oxidation of the tertiary amine to the corresponding amine N-oxide as the dominant initial pathway.\n\nC. Cytochrome P450 (CYP)-mediated hydroxylation at the methine carbon of the isopropyl group (the tertiary C–H) to yield a tertiary alcohol.\n\nD. Direct hydrolytic cleavage of a C–N bond of the tertiary amine to remove an alkyl group without prior oxidation.\n\nE. Alcohol dehydrogenase-mediated oxidation of the isopropyl substituent to a ketone as the initiating step.", "solution": "The user wants me to solve the problem.\n**Step 1: Extract Givens**\n- Substrate: A lipophilic, overall neutral small-molecule drug.\n- Functional Group 1: A single tertiary aliphatic amine.\n- Condition for Functional Group 1: The amine bears at least one $\\alpha$-carbon with C–H bonds.\n- Functional Group 2: A remote isopropyl group.\n- Condition for Functional Group 2: Attached to a saturated, non-benzylic, non-allylic carbon.\n- Reaction Conditions: Incubation with human liver microsomes.\n- Task: Predict the most likely first transformation.\n- Required Justification: Compare bond dissociation energies (BDEs) and electronic factors at the candidate sites.\n- Constraint: Select the single best answer.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is firmly grounded in the principles of drug metabolism, a core topic in pharmacology and medicinal chemistry. It involves well-established enzyme families (Cytochrome P450s, Flavin-containing monooxygenases) found in human liver microsomes and their known catalytic mechanisms (C-H oxidation, N-oxidation, N-dealkylation). The use of bond dissociation energy (BDE) and electronic factors to predict regioselectivity of metabolic reactions is a standard and scientifically valid approach.\n- **Well-Posedness:** The problem provides a clear chemical scenario with two distinct, competing sites for metabolism: (1) the tertiary amine and its $\\alpha$-carbons, and (2) the remote isopropyl group. The qualifiers \"lipophilic,\" \"neutral,\" \"tertiary aliphatic,\" \"remote,\" and \"non-benzylic, non-allylic\" are precise and sufficient to allow for a reasoned comparison of reaction likelihoods based on established chemical principles. The question asks for the \"most likely\" outcome, which translates to a kinetic preference, a solvable problem.\n- **Objectivity:** The problem is stated using objective, technical language. There are no subjective or ambiguous terms.\n\nThe problem statement is internally consistent, scientifically sound, and well-posed. No flaws are identified.\n\n**Verdict:** The problem is valid.\n\n**Derivation of Solution**\n\nThe problem requires us to determine the most probable initial Phase I metabolic transformation of a drug molecule containing two potential sites for oxidation: a tertiary aliphatic amine and a remote, unactivated isopropyl group. The reaction is carried out in human liver microsomes, which are rich in Phase I oxidative enzymes, primarily the Cytochrome P450 (CYP) superfamily and the Flavin-containing Monooxygenase (FMO) family.\n\nWe must compare the relative reactivity of the different positions on the drug molecule towards these enzymes. The primary candidate sites for oxidation are:\n1.  The nitrogen atom of the tertiary amine (leading to N-oxidation).\n2.  The C-H bonds on the carbon atom(s) $\\alpha$ to the tertiary amine (leading to N-dealkylation).\n3.  The C-H bonds of the isopropyl group, specifically the tertiary (methine) C-H bond.\n\nLet's analyze the reactivity of these sites based on electronic factors and bond dissociation energies (BDEs).\n\n**Comparison of C-H Bond Reactivity for CYP-mediated Oxidation:**\nCYP-catalyzed oxidation of C-H bonds typically proceeds through a hydrogen atom transfer (HAT) mechanism. The rate of this step is inversely related to the strength of the C-H bond being broken, which is quantified by its BDE. A lower BDE corresponds to a weaker bond, a lower activation energy, and a faster reaction rate.\n\n-   **Site 3 (Isopropyl Group):** The isopropyl group is described as \"remote\" and attached to a \"saturated, non-benzylic, non-allylic carbon.\" This means it is electronically unactivated. The tertiary C-H bond at the methine position is the most likely site of attack within this group (tertiary C-H bonds are weaker than secondary or primary ones). The BDE of a tertiary C-H bond in a typical alkane is approximately $96.5 \\text{ kcal/mol}$.\n\n-   **Site 2 ($\\alpha$-Carbon to Amine):** The drug possesses a tertiary amine with at least one $\\alpha$-carbon bearing C-H bonds. A C-H bond positioned $\\alpha$ to a nitrogen atom is significantly weakened. This is due to the stabilizing effect of the adjacent nitrogen lone pair on the incipient carbon-centered radical formed after hydrogen abstraction. This resonance-like stabilization (or hyperconjugation) lowers the energy of the transition state. The BDE for a C-H bond $\\alpha$ to a tertiary amine is in the range of $85 - 90 \\text{ kcal/mol}$.\n\n**Kinetic Comparison:** The BDE of the C-H bond $\\alpha$ to the amine (ca. $85-90 \\text{ kcal/mol}$) is substantially lower than that of the tertiary C-H bond on the remote isopropyl group (ca. $96.5 \\text{ kcal/mol}$). This difference of $>6 \\text{ kcal/mol}$ translates to a large difference in reaction rates, making the hydrogen abstraction at the $\\alpha$-carbon to the nitrogen kinetically much more favorable. Therefore, CYP-mediated oxidation will preferentially occur at the position $\\alpha$ to the amine, rather than at the remote isopropyl group.\n\n**Mechanism following $\\alpha$-Carbon Oxidation:**\nWhen a CYP enzyme abstracts a hydrogen from the $\\alpha$-carbon, it generates an $\\alpha$-aminoalkyl radical. This rapidly recombines with the activated oxygen species of the CYP heme ($[\\text{Fe(IV)=O}]^{\\cdot+}$) to form a carbinolamine (or hemiaminal ether). A carbinolamine, having a hydroxyl group and an amine attached to the same carbon, is inherently unstable and spontaneously decomposes. This decomposition involves cleavage of the C-N bond, resulting in a secondary amine and a carbonyl compound (an aldehyde or ketone, depending on the substitution of the $\\alpha$-carbon). This entire sequence is termed **oxidative N-dealkylation**.\n\n**Comparison with Other Pathways:**\n-   **FMO-mediated N-oxidation (Site 1):** Tertiary amines are also excellent substrates for FMOs, which directly oxidize the nucleophilic nitrogen lone-pair to form a tertiary amine N-oxide. This is a competing pathway. The drug is described as \"lipophilic\" and \"overall neutral,\" which are favorable characteristics for FMO substrates. However, CYP-mediated N-dealkylation is an extremely facile and common pathway for tertiary amines that possess $\\alpha$-hydrogens, often dominating over N-oxidation. The prompt's emphasis on comparing BDEs as part of the justification lends weight to a mechanism initiated by C-H abstraction (N-dealkylation) over one initiated by direct heteroatom attack (N-oxidation).\n\n-   **Hydrolysis:** The direct hydrolytic cleavage of a stable C-N single bond in an aliphatic amine does not occur under physiological conditions and is not a recognized Phase I metabolic pathway.\n\n-   **Alcohol Dehydrogenase (ADH):** ADH enzymes oxidize alcohols. Since the starting material is not an alcohol, ADH cannot be responsible for the *initial* transformation.\n\n**Conclusion:** Based on the large difference in BDEs, the most reactive site on the molecule towards oxidative attack is the C-H bond on the carbon $\\alpha$ to the tertiary amine. The established mechanism for oxidation at this site by CYP enzymes is oxidative N-dealkylation, which proceeds through a carbinolamine intermediate. This pathway is kinetically favored over C-hydroxylation at the remote, unactivated isopropyl group. While FMO-mediated N-oxidation is plausible, CYP-mediated N-dealkylation is a highly probable, often dominant, pathway for such structures and is directly supported by the requested BDE analysis.\n\n**Option-by-Option Analysis**\n\n**A. Cytochrome P450 (CYP)-mediated oxidative N-dealkylation initiated by hydrogen abstraction at the carbon $\\alpha$ to the tertiary amine, proceeding through a carbinolamine that fragments to a secondary amine and a carbonyl compound.**\n-   **Analysis:** This option correctly identifies the most likely enzyme family (CYP), the most reactive site (carbon $\\alpha$ to the amine, due to electronic activation and low BDE), and the correct subsequent mechanistic steps (carbinolamine formation and fragmentation). This represents the kinetically favored pathway.\n-   **Verdict:** Correct.\n\n**B. Flavin-containing monooxygenase (FMO)-mediated N-oxidation of the tertiary amine to the corresponding amine N-oxide as the dominant initial pathway.**\n-   **Analysis:** This describes a plausible metabolic pathway. FMOs do oxidize tertiary amines to N-oxides. However, for a substrate with accessible $\\alpha$-hydrogens, CYP-mediated N-dealkylation is an extremely competitive and often dominant pathway. The BDE argument strongly favors a C-H abstraction mechanism like that in option A over direct N-oxidation. Thus, while possible, it is arguably not the *most* likely first transformation compared to the highly facile N-dealkylation pathway.\n-   **Verdict:** Incorrect.\n\n**C. Cytochrome P450 (CYP)-mediated hydroxylation at the methine carbon of the isopropyl group (the tertiary C–H) to yield a tertiary alcohol.**\n-   **Analysis:** As established by the BDE comparison, the C-H bond at this remote, unactivated position ($\\text{BDE} \\approx 96.5 \\text{ kcal/mol}$) is much stronger and less reactive than the C-H bond $\\alpha$ to the amine ($\\text{BDE} \\approx 85-90 \\text{ kcal/mol}$). Therefore, this pathway is kinetically disfavored and unlikely to be the primary metabolic route.\n-   **Verdict:** Incorrect.\n\n**D. Direct hydrolytic cleavage of a C–N bond of the tertiary amine to remove an alkyl group without prior oxidation.**\n-   **Analysis:** This is mechanistically incorrect. The C-N bond in a saturated aliphatic amine is robust and not susceptible to hydrolysis under physiological conditions. Cleavage requires prior oxidation to an unstable intermediate like a carbinolamine.\n-   **Verdict:** Incorrect.\n\n**E. Alcohol dehydrogenase-mediated oxidation of the isopropyl substituent to a ketone as the initiating step.**\n-   **Analysis:** Alcohol dehydrogenases (ADHs) require an alcohol as a substrate. The drug molecule as described has an alkyl (isopropyl) group, not an alcohol. ADH cannot perform the initial oxidation of an alkane. This cannot be the initiating step.\n-   **Verdict:** Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4548577"}, {"introduction": "Once a metabolic pathway is identified, the next critical step is to quantify its efficiency. This practice moves from qualitative prediction to quantitative analysis by focusing on the core parameters of enzyme kinetics. Using data from a typical *in vitro* microsomal experiment, you will calculate the maximal velocity ($V_{max}$) and the fundamentally important metric of intrinsic clearance ($CL_{int}$), providing a quantitative basis for how quickly an enzyme can process its substrate under different conditions [@problem_id:4548601].", "problem": "A neutral, lipophilic probe substrate undergoing a cytochrome P450-mediated Phase I oxidation in pooled human liver microsomes is characterized under initial-rate conditions at $37\\,^{\\circ}\\mathrm{C}$. The microsomal protein-normalized maximal velocity is measured as $V_{max} = 200$ pmol min$^{-1}$ mg$^{-1}$, and the Michaelis constant is $K_{m} = 10$ $\\mu$M. Assume classical single-enzyme Michaelis–Menten behavior under steady-state conditions, negligible nonspecific binding, and that measurements are made in the linear initial-rate regime. Using only standard enzyme kinetic definitions, determine:\n- the intrinsic clearance $CL_{int}$, defined as the limiting slope of the velocity–substrate concentration relationship as substrate concentration approaches zero, and\n- the initial metabolic rate $v$ at substrate concentration $S = 5$ $\\mu$M.\n\nExpress $CL_{int}$ in $\\mu$L min$^{-1}$ mg$^{-1}$ protein and $v$ in pmol min$^{-1}$ mg$^{-1}$ protein. Round both requested quantities to three significant figures. Report your answers ordered as $(CL_{int}, v)$.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- **System**: A neutral, lipophilic probe substrate undergoing a cytochrome P450-mediated Phase I oxidation in pooled human liver microsomes.\n- **Conditions**: Initial-rate conditions at a temperature of $37\\,^{\\circ}\\mathrm{C}$.\n- **Kinetic Parameters**:\n  - Maximal velocity, $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$.\n  - Michaelis constant, $K_{m} = 10 \\text{ } \\mu\\text{M}$.\n- **Assumptions**:\n  - Classical single-enzyme Michaelis–Menten behavior.\n  - Steady-state conditions.\n  - Negligible nonspecific binding.\n  - Measurements are made in the linear initial-rate regime.\n- **Definitions and Tasks**:\n  1. Determine the intrinsic clearance, $CL_{int}$, defined as \"the limiting slope of the velocity–substrate concentration relationship as substrate concentration approaches zero\".\n  2. Determine the initial metabolic rate, $v$, at a substrate concentration of $S = 5 \\text{ } \\mu\\text{M}$.\n- **Output Requirements**:\n  - Express $CL_{int}$ in units of $\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$ protein.\n  - Express $v$ in units of pmol min$^{-1}$ mg$^{-1}$ protein.\n  - Round both quantities to three significant figures.\n  - Report the answers in the order $(CL_{int}, v)$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Groundedness**: The problem is firmly grounded in the principles of enzyme kinetics and pharmacology. The scenario, involving cytochrome P450 enzymes in human liver microsomes, and the kinetic parameters ($V_{max}$, $K_m$) are standard and realistic for in vitro drug metabolism studies.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary data and clear definitions based on the Michaelis–Menten model to uniquely determine the requested quantities.\n- **Objectivity**: The problem is stated using precise, objective, and quantitative language, devoid of any subjectivity or bias.\n- **Completeness and Consistency**: The problem is self-contained and internally consistent. The assumptions provided are standard for simplifying the system to a solvable model.\n- **Realism**: The values for $V_{max}$ and $K_m$ are entirely plausible for a P450-mediated reaction.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and complete. It is therefore deemed **valid**. A solution will be derived.\n\nThe kinetics of the reaction are described by the Michaelis–Menten equation, which relates the initial reaction velocity $v$ to the substrate concentration $S$:\n$$v = \\frac{V_{max} S}{K_m + S}$$\nwhere $V_{max}$ is the maximal velocity and $K_m$ is the Michaelis constant.\n\n**1. Determination of Intrinsic Clearance ($CL_{int}$)**\n\nThe problem defines intrinsic clearance, $CL_{int}$, as the limiting slope of the velocity–substrate concentration relationship as $S$ approaches zero. This can be interpreted as the initial slope of the $v$ versus $S$ curve, which is the derivative $\\frac{dv}{dS}$ evaluated at $S=0$. Let us compute this derivative using the quotient rule:\n$$\\frac{dv}{dS} = \\frac{d}{dS}\\left(\\frac{V_{max} S}{K_m + S}\\right) = \\frac{V_{max}(K_m + S) - (V_{max} S)(1)}{(K_m + S)^2} = \\frac{V_{max} K_m}{(K_m + S)^2}$$\nTaking the limit as $S \\to 0$:\n$$CL_{int} = \\lim_{S \\to 0} \\frac{dv}{dS} = \\frac{V_{max} K_m}{(K_m + 0)^2} = \\frac{V_{max}}{K_m}$$\nAlternatively, clearance is defined as the rate of elimination divided by the concentration, $v/S$. Intrinsic clearance is the limit of this ratio at low substrate concentrations:\n$$CL_{int} = \\lim_{S \\to 0} \\frac{v}{S} = \\lim_{S \\to 0} \\frac{V_{max} S}{S(K_m + S)} = \\lim_{S \\to 0} \\frac{V_{max}}{K_m + S} = \\frac{V_{max}}{K_m}$$\nBoth interpretations yield the same, standard result.\n\nThe given values are $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$ and $K_m = 10 \\text{ } \\mu\\text{M}$. To obtain $CL_{int}$ in the required units of $\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$, we must perform a unit conversion for $K_m$.\n$$1 \\text{ M} = 1 \\text{ mol L}^{-1}$$\n$$K_m = 10 \\text{ } \\mu\\text{M} = 10 \\frac{\\mu\\text{mol}}{\\text{L}}$$\nWe convert the units to match those in $V_{max}$ (picomoles) and the desired output (microliters).\n$$1 \\text{ }\\mu\\text{mol} = 10^6 \\text{ pmol}$$\n$$1 \\text{ L} = 10^6 \\text{ }\\mu\\text{L}$$\nTherefore, the concentration unit conversion is:\n$$1 \\frac{\\mu\\text{mol}}{\\text{L}} = \\frac{10^6 \\text{ pmol}}{10^6 \\text{ }\\mu\\text{L}} = 1 \\frac{\\text{pmol}}{\\mu\\text{L}}$$\nSo, $K_m = 10 \\text{ pmol } \\mu\\text{L}^{-1}$.\n\nNow we can calculate $CL_{int}$:\n$$CL_{int} = \\frac{V_{max}}{K_m} = \\frac{200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}}{10 \\text{ pmol } \\mu\\text{L}^{-1}} = 20 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$$\nThe problem requires rounding to three significant figures. Thus, $CL_{int} = 20.0 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$.\n\n**2. Determination of Initial Metabolic Rate ($v$)**\n\nThe initial metabolic rate $v$ at a substrate concentration of $S = 5 \\text{ } \\mu\\text{M}$ is calculated by direct substitution into the Michaelis–Menten equation.\nThe parameters are:\n- $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$\n- $K_m = 10 \\text{ } \\mu\\text{M}$\n- $S = 5 \\text{ } \\mu\\text{M}$\n\nSince $K_m$ and $S$ have the same units ($\\mu\\text{M}$), they can be used directly in the equation, and the resulting units for $v$ will be the units of $V_{max}$.\n$$v = \\frac{V_{max} S}{K_m + S} = \\frac{(200 \\text{ pmol min}^{-1} \\text{ mg}^{-1})(5 \\text{ }\\mu\\text{M})}{10 \\text{ }\\mu\\text{M} + 5 \\text{ }\\mu\\text{M}}$$\n$$v = \\frac{200 \\times 5}{10 + 5} \\text{ pmol min}^{-1} \\text{ mg}^{-1} = \\frac{1000}{15} \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\n$$v = \\frac{200}{3} \\text{ pmol min}^{-1} \\text{ mg}^{-1} \\approx 66.666... \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\nRounding to three significant figures, we get:\n$$v = 66.7 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\n\nThe final results, ordered as specified, are $CL_{int} = 20.0 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$ and $v = 66.7 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 20.0 & 66.7 \\end{pmatrix}}\n$$", "id": "4548601"}, {"introduction": "The ultimate goal of studying drug metabolism is to improve patient outcomes, which requires understanding how individual differences affect drug response. This advanced practice bridges the gap from enzyme kinetics to clinical pharmacogenomics, demonstrating how genetic polymorphisms in a key Phase I enzyme, CYP2C19, can alter drug activation and therapeutic efficacy. By combining principles of population genetics with pharmacokinetic-pharmacodynamic modeling, you will predict the average clinical response in a population, highlighting the profound real-world impact of metabolic variability [@problem_id:4548462].", "problem": "A prodrug used for antiplatelet therapy requires oxidative bioactivation by cytochrome P450 2C19 (CYP2C19), a Phase I reaction. Two loss-of-function alleles, denoted $\\ast 2$ and $\\ast 3$, abolish or significantly reduce CYP2C19-mediated formation of the active metabolite. Consider a large, randomly mating population in Hardy–Weinberg equilibrium with the following allele frequencies for CYP2C19: loss-of-function allele frequencies $f_{\\ast 2} = 0.15$ and $f_{\\ast 3} = 0.05$, and functional wild-type allele frequency $f_{\\ast 1} = 1 - (f_{\\ast 2} + f_{\\ast 3})$. Assume that $\\ast 2$ and $\\ast 3$ are functionally equivalent and independent for the purpose of phenotype classification into three metabolizer categories: normal metabolizer (NM, genotype $\\ast 1/\\ast 1$), intermediate metabolizer (IM, any one loss-of-function allele with one functional allele, that is $\\ast 1/\\ast 2$ or $\\ast 1/\\ast 3$), and poor metabolizer (PM, two loss-of-function alleles, that is $\\ast 2/\\ast 2$, $\\ast 2/\\ast 3$, or $\\ast 3/\\ast 3$).\n\nThe pharmacodynamic effect (fractional platelet inhibition) is modeled by a maximum-effect model: for active metabolite exposure $A$, the inhibition is \n$$\nI \\;=\\; I_{\\max}\\,\\frac{A}{A + EC_{50}},\n$$\nwhere $I_{\\max}$ is the maximal attainable inhibition and $EC_{50}$ is the exposure that yields half of $I_{\\max}$. Suppose $I_{\\max} = 0.7$, $EC_{50} = 50$ exposure units, and that exposure depends on CYP2C19 phenotype as follows: for NM, $A_{\\text{NM}} = 100$ units; for IM, $A_{\\text{IM}} = \\alpha\\,A_{\\text{NM}}$ with $\\alpha = 0.5$; and for PM, $A_{\\text{PM}} = \\beta\\,A_{\\text{NM}}$ with $\\beta = 0.1$.\n\nUsing only the fundamental assumptions above (Hardy–Weinberg equilibrium for multi-allelic loci and the stated pharmacodynamic model), first determine the genotype category frequencies implied by the allele frequencies, then use them to compute the population-average fractional platelet inhibition $\\bar{I}$ as the expectation of $I$ over the three categories. Express the final answer for $\\bar{I}$ as a unitless decimal fraction, rounded to four significant figures. Do not use a percent sign.", "solution": "The problem is valid as it is scientifically grounded in established principles of population genetics (Hardy–Weinberg equilibrium) and pharmacology (pharmacogenomics and enzyme kinetics), is well-posed with all necessary information provided, and is expressed in objective, formal language.\n\nThe solution requires a multi-step calculation. First, we determine the frequencies of the three metabolizer phenotypes (Normal, Intermediate, and Poor) based on the supplied allele frequencies and the assumption of Hardy–Weinberg equilibrium. Second, we calculate the active metabolite exposure and the resulting fractional platelet inhibition for each phenotype. Finally, we compute the population-average platelet inhibition by taking the expectation of inhibition, weighted by the phenotype frequencies.\n\nLet the frequencies of the alleles $\\ast 1$, $\\ast 2$, and $\\ast 3$ be denoted by $p$, $q$, and $r$, respectively.\nThe problem provides the frequencies of the loss-of-function alleles:\n$q = f_{\\ast 2} = 0.15$\n$r = f_{\\ast 3} = 0.05$\n\nThe frequency of the functional wild-type allele, $p = f_{\\ast 1}$, is determined by the fact that the sum of all allele frequencies must be $1$:\n$$\np = 1 - (q + r) = 1 - (0.15 + 0.05) = 1 - 0.20 = 0.80\n$$\n\nThe population is in Hardy–Weinberg equilibrium. For a three-allele system, the genotype frequencies are given by the terms in the expansion of $(p + q + r)^2 = 1$. We can now calculate the frequency of each metabolizer phenotype.\n\n1.  **Normal Metabolizer (NM)**: The genotype is $\\ast 1/\\ast 1$. Its frequency, $f_{\\text{NM}}$, is:\n    $$\n    f_{\\text{NM}} = p^2 = (0.80)^2 = 0.64\n    $$\n\n2.  **Intermediate Metabolizer (IM)**: The genotypes are $\\ast 1/\\ast 2$ and $\\ast 1/\\ast 3$. Its frequency, $f_{\\text{IM}}$, is the sum of the frequencies of these two heterozygous genotypes:\n    $$\n    f_{\\text{IM}} = 2pq + 2pr = 2p(q + r) = 2(0.80)(0.15 + 0.05) = 2(0.80)(0.20) = 0.32\n    $$\n\n3.  **Poor Metabolizer (PM)**: The genotypes are any combination of two loss-of-function alleles: $\\ast 2/\\ast 2$, $\\ast 3/\\ast 3$, or $\\ast 2/\\ast 3$. Its frequency, $f_{\\text{PM}}$, is the sum of the frequencies of these three genotypes:\n    $$\n    f_{\\text{PM}} = q^2 + r^2 + 2qr = (q+r)^2 = (0.15 + 0.05)^2 = (0.20)^2 = 0.04\n    $$\nAs a check, the sum of the phenotype frequencies is $f_{\\text{NM}} + f_{\\text{IM}} + f_{\\text{PM}} = 0.64 + 0.32 + 0.04 = 1.00$.\n\nNext, we calculate the active metabolite exposure, $A$, for each phenotype.\nFor NM: $A_{\\text{NM}} = 100$ units.\nFor IM: $A_{\\text{IM}} = \\alpha A_{\\text{NM}} = 0.5 \\times 100 = 50$ units.\nFor PM: $A_{\\text{PM}} = \\beta A_{\\text{NM}} = 0.1 \\times 100 = 10$ units.\n\nNow, we calculate the fractional platelet inhibition, $I$, for each phenotype using the provided maximum-effect model: $I = I_{\\max}\\frac{A}{A + EC_{50}}$, with $I_{\\max} = 0.7$ and $EC_{50} = 50$.\n\nFor NM:\n$$\nI_{\\text{NM}} = 0.7 \\times \\frac{A_{\\text{NM}}}{A_{\\text{NM}} + 50} = 0.7 \\times \\frac{100}{100 + 50} = 0.7 \\times \\frac{100}{150} = 0.7 \\times \\frac{2}{3} = \\frac{1.4}{3}\n$$\n\nFor IM:\n$$\nI_{\\text{IM}} = 0.7 \\times \\frac{A_{\\text{IM}}}{A_{\\text{IM}} + 50} = 0.7 \\times \\frac{50}{50 + 50} = 0.7 \\times \\frac{50}{100} = 0.7 \\times \\frac{1}{2} = 0.35\n$$\n\nFor PM:\n$$\nI_{\\text{PM}} = 0.7 \\times \\frac{A_{\\text{PM}}}{A_{\\text{PM}} + 50} = 0.7 \\times \\frac{10}{10 + 50} = 0.7 \\times \\frac{10}{60} = 0.7 \\times \\frac{1}{6} = \\frac{0.7}{6}\n$$\n\nFinally, the population-average fractional platelet inhibition, $\\bar{I}$, is the expected value of $I$, calculated as the sum of the phenotype-specific inhibitions weighted by their respective frequencies:\n$$\n\\bar{I} = E[I] = f_{\\text{NM}}I_{\\text{NM}} + f_{\\text{IM}}I_{\\text{IM}} + f_{\\text{PM}}I_{\\text{PM}}\n$$\nSubstituting the calculated values:\n$$\n\\bar{I} = (0.64)\\left(\\frac{1.4}{3}\\right) + (0.32)(0.35) + (0.04)\\left(\\frac{0.7}{6}\\right)\n$$\n$$\n\\bar{I} = \\frac{0.896}{3} + 0.112 + \\frac{0.028}{6}\n$$\nTo simplify, we find a common denominator of $6$:\n$$\n\\bar{I} = \\frac{2 \\times 0.896}{6} + \\frac{6 \\times 0.112}{6} + \\frac{0.028}{6}\n$$\n$$\n\\bar{I} = \\frac{1.792}{6} + \\frac{0.672}{6} + \\frac{0.028}{6}\n$$\n$$\n\\bar{I} = \\frac{1.792 + 0.672 + 0.028}{6} = \\frac{2.492}{6}\n$$\n$$\n\\bar{I} \\approx 0.415333...\n$$\nRounding the result to four significant figures, as requested, gives:\n$$\n\\bar{I} = 0.4153\n$$\nThis is the population-average fractional platelet inhibition.", "answer": "$$\\boxed{0.4153}$$", "id": "4548462"}]}